NCT05409482|Recruiting
Loading search results
Sponsor study identifier
observational
300
1 country
1
Study Start
August 20, 2022
Actual (reported)Primary Completion
March 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
To evaluate the efficacy and safety of camrelizumab combined with apatinib mesylate in the treatment of unresectable hepatocellular carcinoma.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 25, 2022
Actual (reported)June 8, 2022
Actual (reported)August 20, 2022
Actual (reported)March 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
March 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Progression-free survival（PFS）
PFS was defined as the subject's date from the date of the first dose to the date of the first documented tumor progression (as assessed by mRECIST criteria, with or without continuation of treatment) or the date of death from any cause, whichever occurred first.
Up to 2 years
Objective response rate（ORR）
Up to 2 years
Disease control rate（DCR）
Up to 2 years
Overall survival（OS）
Up to 8 years
Occurence of AE and SAE
Up to 2 years
Patients with unresectable hepatocellular carcinoma
Mengchao Hepatobiliary Hospital, Fujian Medical University
Fuzhou, Fujian, China
Wu h Guo
Mengchao Hepatobiliary Hospital, Fujian Medical University
Zhi bo Zhang
First Affiliated Hospital of Fujian Medical University
Yi p Chen
First Affiliated Hospital of Fujian Medical University
Ning Huang
Union Hospital, Affiliated to Fujian Medical University
First Submitted
May 25, 2022
First Posted
June 8, 2022
Study Start
August 20, 2022
Actual (reported)Primary Completion
March 1, 2026
Estimated (date passed)Contact the study team to confirm eligibility.
Mao l Yan
Fujian Provincial Hospital
Zhu t Fang
Fujian Provincial Hospital
Hui Zhang
Fujian Cancer Hospital
Xiao j Zhang
The 900th Hospital of the Joint Logistics Support Force
Ling q Yan
Fuqing City Hospital
Yan m Zhou
The First Affiliated Hospital of Xiamen University
Yong yi Zeng
Mengchao Hepatobiliary Hospital, Fujian Medical University
Ping g Liu
Zhongshan Hospital Affiliated to Xiamen University
Fu q Wang
Xiamen Hospital of Traditional Chinese Medicine
Bo h Zhang
Zhongshan Hospital (Xiamen), Fudan University
Cong r Wang
Quanzhou First Hospital
Wei Wang
The Second Affiliated Hospital of Fujian Medical University
Yu f Chen
Zhangzhou Hospital
Shao w Zhuang
Zhangzhou Hospital
Jian f Zhao
The Affiliated Hospital of Putian University
Jia f Chen
Putian First Hospital
Wen l Zeng
Longyan Second Hospital
Yong z Wang
Sanming Second Hospital
Wen f Wu
Nanping Second Hospital
Wen x Xie
Fuding City Hospital
Feng Lin
Ningde Mindong Hospital
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
May 13, 2025
Record last verified: 2025-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: